Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
30 sept. 2024 16h05 HE
|
Gritstone bio
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21%...
Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
13 août 2024 16h05 HE
|
Gritstone bio
-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer...
Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
24 juil. 2024 07h00 HE
|
Gritstone bio
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) --...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 juil. 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 juin 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
04 juin 2024 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
09 mai 2024 16h05 HE
|
Gritstone bio
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic,...
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
02 mai 2024 16h05 HE
|
Gritstone bio
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to...
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
30 avr. 2024 07h00 HE
|
Gritstone bio
-- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the...
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
29 avr. 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...